Central Repository Created for SARS-CoV 2 Clinical Trials
Inato has unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2.
- By BSTQ Staff
Inato, a marketplace that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, has unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2 (the virus that causes COVID-19). The anticovid platform is public, free to access and offers extensive search and filtering capabilities. The purpose of the platform is to provide the global healthcare community with easy and efficient access to any available COVID-19 trial information and research trends. In addition, the platform analyzes the latest COVID-19 clinical trial information, providing platform subscribers new analyses twice per week. In mid-April, the platform deduced:
- Nearly 1,000 COVID-19 trials were launched or anticipated in the previous four months, equating to an average of 210 trials per month.
- While China is responsible for most trials, other highly affected developed countries such as Italy, France and the U.S. have significantly increased their trials.
- Early signals suggest some antiviral agents could be ineffective for treating COVID-19 (at least in seriously ill patients); however, a significant focus of trials remains on those drugs.
- The most frequently tested therapeutic classes are antiviral agents chloroquine/hydroxychloroquine and traditional/Chinese medicine.
“We’ve been tracking COVID-19 clinical trials since January and noticed how difficult it was to consolidate, compare and take action on the hundreds upon hundreds of trials being developed,” said Inato CoFounder and CEO Kourosh Davarpanah. “Our company’s objective is to bring new doctors and their patients into the clinical research ecosystem to unlock the potential of unengaged research sites so biopharma can bring innovative therapies to market faster. With our anticovid platform, we’re taking things one step further by centralizing all COVID-19 clinical trial information and making it easy to navigate so that clinical researchers, physicians and biopharma companies can more efficiently participate in the fight for a cure.”
Individuals can access Inato’s anticovid platform, register for weekly analysis updates and submit feedback at covid.inato.com/analysis.
